Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 147 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chronic Kidney Disease (Chronic Renal Failure) Overview 10
Therapeutics Development 11
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 11
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 12
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 13
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 16
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 20
Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 22
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 23
Hospira, Inc. 23
AstraZeneca PLC 24
Eli Lilly and Company 25
Quark Pharmaceuticals, Inc. 26
Astellas Pharma Inc. 27
OPKO Health, Inc. 28
Toray Industries, Inc. 29
Evotec AG 30
NPS Pharmaceuticals, Inc. 31
La Jolla Pharmaceutical Company 32
Alexion Pharmaceuticals, Inc. 33
AFFiRiS AG 34
Acceleron Pharma, Inc. 35
Nippon Zoki Pharmaceutical Co., Ltd. 36
Catabasis Pharmaceuticals, Inc. 37
Angion Biomedica Corp. 38
Concert Pharmaceuticals, Inc. 39
Intercept Pharmaceuticals, Inc. 40
Vitae Pharmaceuticals, Inc. 41
TRACON Pharmaceuticals, Inc. 42
Stelic Institute & Co. 43
Vicore Pharma AB 44
Otsuka Holdings Co., Ltd. 45
Sphaera Pharma Pvt. Ltd. 46
Multi Gene Vascular Systems Ltd 47
Bio-inRen 48
Red Glead Discovery AB 49
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
beraprost sodium LA - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cinacalcet hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
epoetin zeta - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
sotatercept - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
eculizumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GCS-100 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
tolvaptan - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tenapanor hydrochloride - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
LY-3016859 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SP-20103 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
VTP-27999 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CTP-499 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
LY-3113593 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
KBP-5074 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
INT-767 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
C-21 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CAT-4000 Series - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ANG-3070 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
MultiGeneGraft - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
CXA-10 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
CAT-4001 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
SphK2 Program - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
(docetaxel + ceramide) - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
AS-2444697 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
NZ-419 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Vida-5 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Vaccine for Chronic Kidney Disease - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecules for Chronic Kidney Disease - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
siRNA for Chronic Diseases - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
STNM-310 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Drug for Kidney Diseases - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Small Molecules for Chronic Kidney Disease - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Drugs to Inhibit CYP24 for CKD and Pre-CKD - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Small Molecules for Chronic Kidney Disease - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Fluorophosphophloretin - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
BRN-1889 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ANG-3557 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Chronic Kidney Disease (Chronic Renal Failure) - Recent Pipeline Updates 116
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 135
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 136
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 137
Featured News & Press Releases 137
Sep 08, 2014: Relypsa Announces Phase 3 Patiromer Data to be Presented in Late-Breaking Session at Heart Failure Society of America 18th Annual Scientific Meeting 137
Aug 11, 2014: Rayaldee Phase 3 Trial Meets Primary Endpoints 137
Jul 21, 2014: Proteon Therapeutics Initiates Phase 3 Clinical Study of PRT-201 in Patients with Chronic Kidney Disease Undergoing Surgical Placement of an Arteriovenous Fistula for Hemodialysis 139
Jul 17, 2014: Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis 140
Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402) 140
Jun 30, 2014: Rockwell Medical Announces FDA Approves $2.2 Million Application Fee Refund for Triferic NDA 141
Jun 18, 2014: ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial 142
Jun 11, 2014: Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen 142
Jun 04, 2014: La Jolla Pharmaceutical Company Announces Completion of Enrollment of Phase 2 Extension Study of GCS-100 in Chronic Kidney Disease 143
May 29, 2014: Akebia Therapeutics Announces Upcoming Presentation at 51st ERA-EDTA Annual Congress 144
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147

List of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2014 11
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2014 22
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Hospira, Inc., H2 2014 23
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca PLC, H2 2014 24
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Company, H2 2014 25
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 26
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H2 2014 27
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health, Inc., H2 2014 28
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H2 2014 29
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H2 2014 30
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by NPS Pharmaceuticals, Inc., H2 2014 31
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2014 32
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2014 33
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AFFiRiS AG, H2 2014 34
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H2 2014 35
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2014 36
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 37
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H2 2014 38
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 39
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 40
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 41
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 42
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., H2 2014 43
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H2 2014 44
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 45
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2014 46
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2014 47
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H2 2014 48
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H2 2014 49
Assessment by Monotherapy Products, H2 2014 50
Assessment by Combination Products, H2 2014 51
Number of Products by Stage and Target, H2 2014 54
Number of Products by Stage and Mechanism of Action, H2 2014 57
Number of Products by Stage and Route of Administration, H2 2014 59
Number of Products by Stage and Molecule Type, H2 2014 61
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Recent Pipeline Updates, H2 2014 116
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2014 135
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2014 136